Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
Licence: CC BY 4.0
ID Serval
serval:BIB_3A4B102DBA12
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine.
Périodique
Cells
Auteur(s)
Laurent A., Abdel-Sayed P., Hirt-Burri N., Scaletta C., Michetti M., de Buys Roessingh A., Raffoul W., Applegate L.A.
ISSN
2073-4409 (Electronic)
ISSN-L
2073-4409
Statut éditorial
Publié
Date de publication
24/09/2021
Peer-reviewed
Oui
Volume
10
Numéro
10
Pages
2526
Langue
anglais
Notes
Publication types: Historical Article ; Journal Article ; Review
Publication Status: epublish
Résumé
The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration.
Mots-clé
Animals, Biological Specimen Banks, Biotechnology/methods, COVID-19 Vaccines, Cell Line, Cell- and Tissue-Based Therapy, Diploidy, History, 20th Century, History, 21st Century, Humans, Lung/cytology, Lung/physiology, Regeneration, Regenerative Medicine/history, Regenerative Medicine/methods, Respiratory Tract Infections/therapy, SARS-CoV-2, Stem Cell Transplantation, Stem Cells/cytology, Transplantation, Homologous, COVID-19, MRC-5 cells, active pharmaceutical ingredient, cell banking, cell therapy, diploid progenitor cells, inflammatory lung disease, lung cells, regenerative medicine, vaccine substrate
Pubmed
Web of science
Open Access
Oui
Création de la notice
30/09/2021 13:14
Dernière modification de la notice
20/11/2021 6:34
Données d'usage